Therapy Areas: Vaccines
RVAC Medicines' phase one, first-in-human study assessing mRNA-based COVID-19 vaccine candidate RVM-V001 doses first participant
22 September 2022 -

RVAC Medicines Pte. Ltd., a Singapore-based messenger RNA (mRNA) technology platform company incubated by CBC Group, announced on Wednesday that it has dosed a participant in a phase one, first-in-human study assessing the company's mRNA-based COVID-19 vaccine candidate, RVM-V001.

The Phase 1 study, an open-label, dose escalation study, is intended to assess the safety and immunogenicity of RVM-V001 in around 54 healthy adults in Australia.

This study is part of a series of clinical trials intended to assess RVAC's range of COVID-19 vaccine candidates that include one against the ancestral strain, one against the Omicron strain and a bivalent vaccine candidate with components of both ancestral and Omicron strains.